Type 2 diabetes patient ethnicity study

The client

  • Our client is a top 10, global pharmaceutical manufacturer with drug products in multiple therapeutic areas.
  • It employs over 50,000 and has an annual revenue of more than $40 billion.

Client need and challenges

  • Our client was looking to segment and compare the type 2 diabetes patient population by ethnicity types: hispanic and non-hispanic ethnicities. The client also needed to profile the hispanic type 2 diabetes patient population, including risk and impactability scores, method of payment (commercial payer/insurer, government, cash, etc.), And individual “sole” vs. Family “cardholder” patient eligibilities. Lastly, the client wanted to quantify hispanic patient populations at the us county geographic level.
  • One obstacle was that the client did not have an industry accepted approach of assessing risk and impactability scores to hispanic patient populations diagnosed with type 2 diabetes, and needed an acceptable approach to isolate “sole or individual” cardholders vs. “Family” cardholders.

EXL Health’s approach and methodology

  • Based on pharmacy claims and eligibility data, EXL Health developed a patient-level benchmark database of us-based, type 2 diabetes patients with two years of history. ICD10 diagnosis codes, method of payment data, patient demographic, and us census data were used to develop the benchmark database. EXL Health then segmented the patient populations by hispanic and non-hispanic ethnicities.
  • EXL Health quantified and deciled hispanic patient populations down to the U.S county geographic level.
  • We then calculated the proprietary risk and impactability scores for the hispanic type 2 diabetes patients. Using a proven methodology, EXL Health determined the distribution of sole or individual cardholders and family cardholders for commercial payers.

Anticipated results & utility

As a result of the study, the client was able to:

  • Refine targeting and messaging for those physicians treating hispanic type 2 diabetes patients
  • Modify messaging based on individual or family-supported patient visits
  • Identify growth areas (i.e., Increasing prevalence) of type 2 diabetes among hispanic patient populations
  • Make appropriate resource allocation and assignment decisions based on volumes of hispanic type 2 diabetes patients at the US county geographic level
  • Improve discussions and negotiations with commercial payers, to include assessing the risk and impactability scores of their members